Pelargonium sidoides

Upper Respiratory infection treatment for children & Adult

Pharmaceutical Group: Herbal Medicine
Dosage Form: Syrup & Tablet

Pelargonium sidoides, a South African plant belonging to the Pelargonium genus, was first identified in Germany in 1972. As time went by, modern medical research discovered many of the numerous mechanisms of action of this unique plant extract.
The active drug substance contained in Peliom is dry root extract of the herb.

INTRODUCTION TO ACUTE UPPER RESPIRATORY

Acute upper respiratory tract infections (URTIs) are the most common diseases treated in general and pediatric primary care practice and affect all age groups, particularly during the winter months.

Indications

• Relieve the symptoms of upper respiratory tract infections including

the Common cold and Sinusitis such as:

Sore throat, Cough and Blocked or runny nose

Presentation
SYRUP: Bottle of 120 ml syrup
Tablet: Box of 30 F.C. Tablets

Dosage

• Syrup

Under 6 years of age: 1.5-3 ml of the syrup three times per day. 
 6-12 years of age: 5 ml of the syrup three times per day
 Over 12 years of age: 5-10 ml of the syrup three times per day.

• Tablets

Adult: 1 Tab three times per day

Contraindications

•  Patients using coagulation-inhibiting drugs
•  Severe hepatic and renal diseases due to lack of adequate data

Precaution 
In order to prevent a relapse, continue the treatment a further 2 – 3 days after relief of symptoms treatment duration should not exceed 2 weeks.

Undesirable effects

•  Gastric pain, heartburn, nausea, diarrhea can be occurred. 
•  Light hemorrhage on gum or nose can be occurred seldom. 
•  Hypersensitivity reaction such as rash, urticaria, and pruritus on skin & membrane can be occurred rarely during first drug delivery. 
•  Serious hypersensitivity reaction can be occurred very rarely with facial edema, dyspnea, and hypotension 
•  When a case needs to monitor AST, ALT, ALP, and GGT levels of patient can be occurred very rarely, but no causality has been identified.

Contraindications

•  Hypersensitivity to the active substance or to any of the excipients
•  Increased tendency to bleeding
•  Patients using coagulation-inhibiting drugs
•  Severe hepatic and renal diseases due to lack of adequate data

Interaction with other medicinal products and other forms of interaction
However drug interactions have not been reported to date, since the drug can affect coagulation factors, coagulation inhibiting effect shall be considered when Anticoagulants are administered together.

Special warnings and precautions

•  In order to prevent a relapse, continue the treatment a further 2 – 3 days after relief of symptoms
•  Treatment duration should not exceed 2 weeks.

A doctor or a qualified health care practitioner should be consulted if:

•  The symptoms persist during the use of the product
•  Your condition does not improve within one week
•  In case of fever lasting for several days
•  In case of shortness of breath or blood in the sputum

Pregnancy and lactation
Safety during pregnancy and lactation has not been established. The use during pregnancy and lactation is not recommended.